Puretech Health Share Discussion Threads

[colinblackbourn] 16/1/2025 17:00

Too busy with their back to back meetings in San Fran to get an RNS out.

[takeiteasy] 16/1/2025 16:58

Back to the drawing board - throw every bit of gold sparkles in the presentation and the buyers all but disappear. Let's hope within the next 3-6 months things may inprove. Deffo own goal not to put out an RNS. If a board member reads ADVFN, it is not too late to make amends and get something out in the next few days!!!

[ohisay] 16/1/2025 15:30

It just speaks volumes that we dont have any RNS's to confirm all these numbers .
They really do seem to have tin ears .

[return_of_the_apeman] 16/1/2025 11:08

Thanks doc

[doctor 69] 16/1/2025 10:55

It was also good to see the phase 2 b trial early results at 12 months noted to be good as well although small numbers at present . So the good thing is you get results in 6 months for phase three and by next year the phase 2 b should have 2 year results

[return_of_the_apeman] 16/1/2025 09:43

Will the phase 3 LYT-100 trial be for 26 weeks? If so then results around the end of H1 2026

Beware - I have plucked these figures from thin air

[bad gateway] 16/1/2025 07:43

Nice miss, good to get one to the upside. Nigh on £300M UKP?
Does make current marketcap a little confusing.

[colinblackbourn] 16/1/2025 07:38

Cash $365m .guidance was $330m

[rimau1] 16/1/2025 07:28

Its nice to be able to re-confirm that the entire marketcap is approx backed by net cash on the balance sheet. One of those rare market freebies albeit i do not have a handle on our likely cashburn, any ideas. As i keep saying to be successfully invested in biotech buy, hold and forget.

[doctor 69] 16/1/2025 07:19

So cash $360 m , royalties of Cobenfy to come in , seaport to ipo,Lyt100 looks like will be a lead treatment for lung fibrosis with sales over $1 billion , several other products and market cap £330 m . Surely this will treble this year as you can't be valued under £1 billion for long .

[takeiteasy] 16/1/2025 05:35

SLide 22 of the presentation is the standout. 12 possible trigger events that may move the dial. They may all be useful/important but for me the most interesting 4 are:

Cobenfy sales levels confirmation
Initiation of Phase 3 LYT-100 trial
Development of oral GLP1 antagonist to compete with Ozempic type market
Gallop phase 1b trial update

[ohisay] 16/1/2025 01:18

The number of listed biotech companies trading at negative enterprise value remains at historic highs!

[takeiteasy] 15/1/2025 20:58

anything new to turn the dial - I am not sure how long the market chooses to ignore things here

[colinblackbourn] 15/1/2025 20:30

$365m...the forecast was $340m.

[colinblackbourn] 15/1/2025 20:29

https://puretechhealth.com/images/PRTCCorpPresentation.pdf

[edwardt] 15/1/2025 19:59

This gives prtc an enterprise value of $70m which I really do not understand!

[edwardt] 15/1/2025 19:56

Think he said year end cash was $360m

[edwardt] 15/1/2025 19:53

Listened in - phase 3 likely end of year for ipf. Walked through phase2b - really impressed by conviction in how good that was.Confirmed not looking to raise money.Should be positively received !

[colinblackbourn] 15/1/2025 16:40

https://investors.puretechhealth.com/events/event-details/puretech-present-43rd-annual-jp-morgan-healthcare-conference/

[ohisay] 15/1/2025 08:47

Interesting commentary on the Sector generally from RTW this morning ..

Highlights from the Investment Manager's quarterly letter:

· The Russell 2000 Biotech Index was +2.5% for the year and remains below levels first reached in 2018, while the number of listed biotech companies trading at negative enterprise value remains at historic highs.

· Interest rate worries dominated, while the results of the first round of Inflation Reduction Act (IRA) drug negotiations were on the better end of expectations.

· The uncertainty surrounding RFK Jr's nomination as Trump's Secretary of Health and Human Services (HHS) became a new reason for some to stay on the sidelines. Considering the scope of the job, guardrails, and players surrounding him, we currently don't expect a change in direction when it comes to FDA's pro-innovation trend.

· M&A was too small to get things going. While billion-dollar-plus acquisition volumes remain near record highs, dollar value dropped to $45B vs $145B in 2023. Despite this, we don't think this spells doom for larger late-stage deals. Merck, Bristol, Roche, Novartis and Sanofi are still on the hunt for revenues this decade and Lilly and Novo are sure to get more aggressive as their obesity revenues grow. IPOs made incremental progress towards normalisation. Consolidation also continued.

· The FDA approved 56 novel drugs this year, shy of last year's record-setting 61, but still one of the highest in history.

· The sector has outperformed the S&P500 in two of the past three Republican first terms, and we would expect no different an outcome today, given the promising science our team are evaluating daily.

[edwardt] 14/1/2025 19:51

also take a peak at royalty pharma share price - hikes divi on positive outlook - cobenfy in the mix there too

[edwardt] 14/1/2025 19:49

BMS ceo on cnbc - cobenfy very well received and they are super excited about it. Got to be a good signal

[colinblackbourn] 14/1/2025 11:29

Cobenfy massive potential https://firstwordpharma.com/story/5927342

[doctor 69] 14/1/2025 09:49

I really can't understand how cheap PRTC are and surely this year they get rerated . But at sub 150 p it does seem a no brainer with so much cash on the bank and I expect big royalties to come in over next few years

[takeiteasy] 14/1/2025 09:12

Healthcare has been so unloved within the insitutional market for the recent past which has not helped anyone not least our PRTC.

On a podcast this week the US investor base is reported to be switching in part from tech to finance and healthcare ETFs (due to tech sanctions, high 10 year yield etc etc)- arguably for the first time in perhaps over a year. I see this morning the first tremors of a small move here.

I suspect this is not unrelated to the wider moves among the global fund managers.
Let's see what response we get from the JPM presentation.

nai etc